Shares of Moderna dropped by a staggering 10.12% to $152.67 at 14:31 EST on Wednesday, after two successive sessions in a row of gains. The Nasdaq Stock Market is sliding 1.38% to $12,409.00, after four sequential sessions in a row of gains, on what up until now seems, an all-around negative trend trading session today.
Moderna’s last close was $169.86, 16.92% below its 52-week high of $178.50.
Moderna’s sales growth is 1428.1% for the present quarter and 13065.3% for the next. The company’s growth estimates for the ongoing quarter is a negative 48.6% and positive 565.7% for the next.
Year-on-year quarterly revenue growth grew by 826.4%, now sitting on 246.7M for the twelve trailing months.
Moderna’s Stock Top and Bottom Yearly Value
Moderna’s stock is valued at $152.67 at 14:31 EST, way under its 52-week high of $178.50 and way above its 52-week low of $17.68.
Moderna’s Moving Average
Moderna’s value is way higher than its 50-day moving average of $96.34 and way above its 200-day moving average of $75.22.
Previous days news about Moderna
Early bet on Moderna sees top european fund gain 65% this year. According to Bloomberg Quint on Mon Dec 7, “A Baillie Gifford & Co. health care fund run by an all-female team has surged past peers to a 65% gain this year, largely thanks to a far-sighted bet on medical stock Moderna Inc.”
Moderna shares rally as Canada doubles vaccine order. According to MarketWatch on Mon Dec 7, “Shares of Moderna Inc. rallied 1.3% in morning trading Monday, after the biotechnology company said the Canadian government has doubled its order commitment for has gained 7.8%.”
Moderna, Pfizer won’t attend white house summit on vaccines. According to Bloomberg Quint on Mon Dec 7, “The two pharmaceutical companies closest to gaining U.S. clearance for a Covid-19 vaccine won’t attend a planned White House summit intended to build confidence in the shots.”
Moderna says Swiss government has increased its Covid vaccine order to 7.5 million doses from 4.5 million. According to MarketWatch on Tue Dec 8, “Moderna Inc. said Tuesday the Swiss government has increased its order for Moderna’s COVID-19 vaccine candidate to 7.5 million doses from an original 4.5 million. Moderna said it’s on track to start delivering the vaccine as soon as it gets the nod from Swiss regulators. “Moderna could ship its COVID-19 vaccine as soon as December if regulatory approval is granted this month,’ the company said in a statement.”